tiprankstipranks
The Fly

Morgan Stanley trims Ardent Health price target, says pullback an ‘overreaction’

Morgan Stanley trims Ardent Health price target, says pullback an ‘overreaction’

Morgan Stanley lowered the firm’s price target on Ardent Health (ARDT) to $22 from $23.50 and keeps an Overweight rating on the shares after Ardent shared headwinds and tailwinds heading into 2025 at an investor conference last week. The stock declined 11% last week, overshooting the 4% negative revision to EBITDA, notes the analyst, who thinks management is “taking a conservative approach” and views the share price response to the preliminary 2025 outlook as an “overreaction.”

Discover the Best Stocks and Maximize Your Portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1